Low Antithrombin III Activity, Nafamostat Monotherapy without Heparin, and Small Filter Size Are Associated with a Shorter Circuit Lifespan in Pediatric Continuous Kidney Replacement Therapy: A Single-Center Retrospective Cohort Study